Quarterly ResultAug 6, 2026, 04:42 PM
Starling Oncology Q2 Revenue $161.3M, Adj. EBITDA Positive; Raises FY26 Guidance
AI Summary
Starling Oncology reported strong financial results for the second quarter of 2026, with consolidated revenue increasing 34.6% to $161.3 million and Adjusted EBITDA turning positive at $229 thousand. The company significantly improved its net loss to $(9.8) million from $(17.0) million year-over-year. Driven by this momentum and key operational highlights such as record Specialty Pharmacy revenue growth and new strategic partnerships, Starling Oncology raised its full-year 2026 guidance for revenue, gross profit, and Adjusted EBITDA.
Key Highlights
- Consolidated revenue for Q2 2026 increased 34.6% to $161.3 million.
- Gross profit rose 55.2% to $27.2 million in Q2 2026.
- Net loss improved to $(9.8) million in Q2 2026 from $(17.0) million in Q2 2025.
- Adjusted EBITDA turned positive at $229 thousand in Q2 2026, up from $(4.1) million.
- Full-year 2026 revenue guidance raised to $650-$670 million from $630-$650 million.
- Full-year 2026 Adjusted EBITDA guidance raised to $2-$7 million from $0-$9 million.
- Specialty Pharmacy revenue grew 58% year-over-year, driven by record Part D fills.
- Achieved exclusivity in California with a major partner, adding 230,000 capitated lives.
Price Impact
More from TOI